Networking In Pharmaceuticals

7 Key Pharma Partnerships and Developments This Month that You Need to Know: 💊 Eli Lilly and Company’s expanded partnerships with Teladoc Health and LifeMD aim to broaden access to its weight loss drug Zepbound, integrating with virtual care platforms and LillyDirect to offer streamlined, lower-cost options for self-paying patients as compounded alternatives face tighter FDA restrictions 💊 Boehringer Ingelheim partnerships with Veeva Systems and Cognizant result in the launch of the One Medicine Platform, a unified system replacing over 20 legacy tools to streamline clinical development, enhance data connectivity, and accelerate the path to new treatments 💊 MENARINI Group and VisualDx are teaming up to boost early detection of BPDCN, a rare blood cancer that often starts with skin lesions, using AI-powered image analysis to help clinicians spot signs sooner and guide patients toward Menarini’s own treatment, ELZONRIS® 💊EMD Serono, Inc. and Medisafe® launched the HIV Resource Center, a digital health platform to enhance medication adherence, provide proactive health monitoring and patient education. By integrating Medisafe’s medication management technology, it streamlines HIV management aiming to improve outcomes 💊Takeda and Health In Her HUE have partnered to improve Black women’s access to clinical trials through WeConnect, Takeda’s digital patient registry. The platform simplifies trial matching with personalized notifications to address the historical lack of diversity in research and promote equity in clinical trials and healthcare outcomes 💊Bayer launched the E-Town Open Innovation Center in Beijing, reinforcing its digital health and biopharma strategy in China. The AI-driven hub focuses on open innovation, clinical-stage medicines, and digital commercialization to enhance healthcare delivery 💊 Novo Nordisk, with the use of Claude AI has dramatically reduced the time needed to generate Clinical Study Reports, from 12 weeks to just 10 minutes, by using generative AI through its NovoScribe platform, allowing experts to shift their focus from manual compilation to high-value review and ideally faster drug development 👇Links to related articles in comments #pharma #digitalhealth #AI

Innovation in AI for drug discovery and development is increasingly coming from partnerships between big pharma and small, tech-focused startups. Just a few years ago, it seemed like the most exciting work was happening at end-to-end techbio startups. But VC funding has dried up for companies that spend years building a platform before they start thinking about the clinic. So the only path left for that kind of deep, innovative rethinking of the drug discovery process is for pharma companies with longer time horizons to partner with innovative startups, not just on individual assets and programs, but on novel capabilities, models and datasets. To help pharma teams find the right partners for this, I built a dataset of detailed AI-for-biopharma company/solution profiles. Based on category-specific frameworks that provide deeper context and enable head-to-head comparison, this resource is designed to help pharma teams build short lists of promising partners in minutes instead of weeks. You can find a link in the first comment below.

⚡ The Next Revolution in Drug Discovery AI isn’t the real disruption in drug discovery. Collaboration is. Last week, four pharma giants (Bristol Myers, Takeda, AbbVie, and J&J) did something unthinkable: They agreed to share proprietary protein–ligand data to train a joint AI model: OpenFold3. AI in isolation has plateaued. R&D costs have exploded. And the next edge in pharma isn’t data ownership, it’s shared intelligence. For decades, secrecy was the moat. Data silos didn’t protect innovation, they suffocated it. No single company holds enough molecular data to train the next generation of models alone. Collaboration has become infrastructure. Why it matters: – Open models can filter failed compounds before they reach a lab bench, saving billions. – Every month saved in discovery is another month patients aren’t waiting. – Faster validation means precision therapies for Alzheimer’s, cancer, and autoimmune disorders can reach people sooner. The last generation of pharma competed on molecules. The next will compete on models. And when those models learn together, medicine accelerates for everyone. 👉 Is collaboration the new competitive advantage, or the end of competition itself? #DrugDiscovery #AIinBiotech #CollaborativeIntelligence #PharmaInnovation #SystemsThinking #SharedIntelligence

No Partner, No Breakthrough: The Hidden Science of Collaborative Drug Innovation Developing a new drug now takes over a decade and up to $2.6 billion, yet most pharmaceutical R&D is still conducted in competitive silos. This systematic literature review challenges that model head-on. Analyzing 737 peer-reviewed studies and distilling insights from 74 high-quality articles spanning nearly 30 years, the authors reveal a striking conclusion: breakthrough innovation in drug discovery and development is overwhelmingly driven by collaboration — yet collaboration remains the exception, not the rule. The review introduces a clear framework for collaborative innovation across the full drug R&D lifecycle, from initiation and implementation to closure, and distinguishes between homogeneous collaborations (similar organizations) and heterogeneous collaborations (industry–academia–public partnerships). Despite high-profile successes — including COVID-19 vaccines, where nearly one-third of candidates emerged from partnerships — data show that only 5% of FDA-approved drugs from top biopharma companies were developed collaboratively. This disconnect exposes a critical gap between what works scientifically and how innovation is organized operationally. By synthesizing decades of fragmented research into a single, structured view, this review offers both strategic guidance for R&D leaders and a roadmap for future research, making a compelling case that the future of drug innovation will belong not to the fastest mover — but to the best collaborator. https://lnkd.in/e8Tvaser